Steroids and risk of osteonecrosis in ALL: Take a break

The Lancet Oncology

Volumn 13, Issue 9, 2012, Pages 855-857

  Van den Heuvel Eibrink, Marry M ^a,b   Pieters, Rob ^a,b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; STEROID;

ACUTE LYMPHOCYTIC LEUKEMIA; BONE NECROSIS; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SENSITIVITY; EVENT FREE SURVIVAL; GENETIC VARIABILITY; HUMAN; LETTER; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; HUMANS; MALE; OSTEONECROSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84865546949     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70315-7     Document Type: Letter

References (14)

1. Mattano LA, Devidas M, Nachman JB, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol 2012, on behalf of the Children's Oncology Group, published online Aug 15. http://dx.doi.org/10.1016/S1470-2045(12)70274-7.
2. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008, 111:2548-2555.
3. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998, 338:1663-1671.
4. Mattano LA, Sather HN, Trigg ME, Nachman JB Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000, 18:3262-3272.
5. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009, 10:957-966. Dutch Childhood Oncology Group.
6. te Winkel ML, Pieters R, Hop WC, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol 2011, 29:4143-4150.
7. Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007, 369:123-131.
8. Eden TO, Pieters R, Richards S Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children. Br J Haematol 2010, 149:722-733. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG).
9. De Moerloose B, Suciu S, Bertrand Y, et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. Blood 2010, 116:36-44. Children's Leukemia Group of the European Organisation for Research and Treatment of Cancer (EORTC).
10. te Winkel ML, Appel IM, Pieters R, van den Heuvel-Eibrink MM Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica 2008, 93:1570-1574.
11. Bürger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)-experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005, 44:220-225.
12. Patel B, Richards SM, Rowe JM, Goldstone AH, Fielding AK High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia 2008, 22:308-312.
13. Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011, 117:2340-2347.
14. Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004, 22:3930-3936.